JSPR
Income statement / Annual
Last year (2025), Jasper Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Jasper Therapeutics Inc's net income was -$75.80 M.
See Jasper Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$1.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$60.52 M
|
$55.82 M
|
$51.79 M
|
$34.63 M
|
$25.42 M
|
$15.88 M
|
$3.62 M
|
| General & Administrative Expenses |
$18.94 M
|
$20.42 M
|
$17.08 M
|
$16.57 M
|
$11.41 M
|
$4.80 M
|
$1.09 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.94 M
|
$20.42 M
|
$17.08 M
|
$16.57 M
|
$11.41 M
|
$4.80 M
|
$1.09 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$79.46 M
|
$76.24 M
|
$68.86 M
|
$51.20 M
|
$36.83 M
|
$20.68 M
|
$4.71 M
|
| Cost And Expenses |
$80.52 M
|
$76.24 M
|
$68.86 M
|
$51.20 M
|
$36.83 M
|
$20.68 M
|
$4.71 M
|
| Interest Income |
$1.74 M
|
$5.06 M
|
$5.20 M
|
$701.00 K
|
$0.00
|
$0.00
|
$533.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.06 M
|
$1.37 M
|
$1.11 M
|
$975.00 K
|
$377.00 K
|
$20.68 M
|
$4.71 M
|
| EBITDA |
-$74.75 M |
-$69.90 M |
-$63.36 M |
-$36.71 M |
-$30.26 M |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.72 M
|
$4.97 M
|
$4.40 M
|
$13.51 M
|
$6.20 M
|
-$10.99 M
|
-$277.00 K
|
| Income Before Tax |
-$75.80 M
|
-$71.27 M
|
-$64.47 M
|
-$37.69 M
|
-$30.64 M
|
-$31.67 M
|
-$4.99 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$75.80 M
|
-$71.27 M
|
-$64.47 M
|
-$37.69 M
|
-$30.64 M
|
-$31.67 M
|
-$4.99 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.95 |
-4.89 |
-6.18 |
-10.33 |
-26.89 |
-183.08 |
0 |
| EPS Diluted |
-3.95 |
-4.89 |
-6.18 |
-10.33 |
-26.89 |
-183.08 |
0 |
| Weighted Average Shares Out |
$19.17 M
|
$14.58 M
|
$10.44 M
|
$3.65 M
|
$1.14 M
|
$172.00 K
|
$176.00 K
|
| Weighted Average Shares Out Diluted |
$15.33 M
|
$14.58 M
|
$10.44 M
|
$3.65 M
|
$1.14 M
|
$172.98 K
|
$176.00 K
|
| Link |
|
|
|
|
|
|
|
